TScan Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 154
- Market Cap
- $292.9M
- Website
- http://www.tscan.com
- Introduction
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease
- Conditions
- Autoimmune DiseasesUlcerative ColitisMultiple SclerosisSclerodermaAnkylosing SpondylitisCeliac DiseaseNon-radiographic Axial Spondyloarthritis (nr-axSpA)Crohn's DiseaseBirdshot Chorioretinitis
- Interventions
- Procedure: Companion blood samples with procedure
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06587828
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology, PLLC, Phoenix, Arizona, United States
🇺🇸Inland Empire Gastroenterology, Murrieta, California, United States
🇺🇸Knowledge Research Center, Orange, California, United States
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Conditions
- HPV - Anogenital Human Papilloma Virus InfectionHPV-Related Squamous Cell CarcinomaHPV-Related Endocervical AdenocarcinomaHPV-Related Anal Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Vulvar Squamous Cell CarcinomaHPV Positive Rectal Squamous Cell CarcinomaHPV-Related Cervical CarcinomaHPV-Associated Vaginal AdenocarcinomaMelanoma
- Interventions
- Biological: TSC-204-A0201Biological: TSC-200-A0201Biological: TSC-204-A0201 + TSC-200-A0201Biological: TSC-204-A0201 + TSC-204-A0101Biological: TSC-204-C0702Biological: TSC-204-A0201 + TSC-204-C0702Biological: TSC-204-C0702 + TSC-203-A0201Biological: TSC-204-A0101Biological: TSC-200-A0201 + TSC-203-A0201Biological: TSC-204-A0201 + TSC-201-B0702Biological: TSC-204-C0702 + TSC-201-B0702Biological: TSC-204-C0702 + TSC-200-A0201Biological: TSC-203-A0201Biological: TSC-204-A0201 + TSC-203-A0201Biological: TSC-204-C0702 + TSC-204-A0101Biological: TSC-203-A0201 + TSC-201-B0702Biological: TSC-200-A0201 + TSC-204-A0101Biological: TSC-200-A0201 + TSC-201-B0702Biological: TSC-203-A0201 + TSC-204-A0101Biological: TSC-201-B0702
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05973487
- Locations
- 🇺🇸
HonorHealth Research and Innovation Institute, Scottsdale, Arizona, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
- Conditions
- Cervical CancerOvarian CancerMelanomaHead and Neck CancerNon Small Cell Lung CancerHPV16 Related Cancers
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT05812027
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
- Conditions
- AMLMyelodysplastic SyndromesALL, Adult
- Interventions
- Other: ControlDrug: SOC + TSC-100Drug: SOC + TSC-101
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05473910
- Locations
- 🇺🇸
UPenn, Philadelphia, Pennsylvania, United States
🇺🇸Mount Sinai, New York, New York, United States
🇺🇸Columbia University, New York, New York, United States
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
- Conditions
- Solid Tumor, Adult
- Interventions
- Procedure: Tumor Biopsy
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05230186
- Locations
- 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors
- Conditions
- Renal Clear Cell Carcinoma
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- TScan Therapeutics, Inc.
- Registration Number
- NCT04680416
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
- Conditions
- Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 InfectionDetermine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- TScan Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04397900
- Locations
- 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States